Group 5 – Preclinical evaluation of biomaterials
Research directions:
- Evaluation of biocompatibility/toxicity of biomaterials in vitro and in vivo
- Study of biomaterials with osteoconductive and osteoinductive properties
- Study of mechanisms of bone healing
- Investigating nanoparticle and macromolecular behavior in biologically relevant environments
- Develop biomaterials for cancer treatment and diagnostics
Group Leader: Antons Sizovs, PhD
- ORCID: 0000-0001-6495-6317
- Google Scholar Profile
- 2012 | PhD in Polymer Chemistry, Virginia Tech, Blacksburg, VA, USA
- 2012-2017 | Post-doc, Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA
- 2018-2020 | Research Associate, Department of Nanomedicine, Houston Methodist, Houston, TX, USA
Fields of expertise:
- Toxicity/biocompatibility studies of biomaterials, small molecules, and biologics in vitro (cells) and in vivo (mice, rats)
- Pharmacokinetic studies in mice and rats
- Fluorescence and X-ray tomography (mice)
- Super-resolution microscopy (STED
BBCE project´s main objective is to establish a joint Baltic Biomaterials Centre of Excellence for advanced biomaterials development based on the long-term strategic cooperation between AO Research Institute Davos, Switzerland (ARI) and Friedrich-Alexander University of Erlangen-Nuremberg, Germany (FAU) on the one hand and RTU RBIDC, LIOS, RSU and RSU IS on the other hand.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 857287